Summary & Overview
HCPCS Q5162: Denosumab-nxxp (bildyos/bilprevda) Injection, 1 mg
HCPCS Level II code Q5162 designates a 1 mg unit of denosumab-nxxp (bildyos/bilprevda), a biosimilar formulation of denosumab used as a parenteral biologic therapy. The availability of a biosimilar option for denosumab has implications for procurement, formulary placement, and cost-containment strategies across payers nationally. This code is relevant where denosumab products are administered in outpatient and ambulatory settings.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the clinical and site-of-service context for denosumab biosimilar injections, and guidance on the types of benchmarks and policy items typically associated with biosimilar injectable biologics. The publication addresses reimbursement benchmarking, coding and billing considerations for unit-based biosimilar dosing, and common administrative issues that affect coverage and claims processing. Clinical context covered includes the role of denosumab biosimilars in conditions where denosumab is indicated and the operational settings where these injections are commonly delivered.
Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and payer-specific coverage rules.
Billing Code Overview
HCPCS Level II code Q5162 describes an injection of denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg. This code represents the billed service for administration of the biosimilar denosumab product in a single 1 mg unit.
-
Service type: Injectable biologic medication administration (denosumab biosimilar)
-
Typical site of service: Ambulatory infusion clinic, physician office, hospital outpatient department, or other facility where parenteral biologic therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult with osteoporosis or bone loss who presents to an outpatient infusion or injection clinic for administration of denosumab biosimilar. The medication Q5162 (injection, denosumab-nxxp, biosimilar, 1 mg) is supplied as a prefilled syringe or vial for subcutaneous injection. Clinical workflow includes verification of indication and recent bone mineral density testing or fracture history, medication reconciliation (noting prior osteoporosis therapies and calcium/vitamin D supplementation), informed consent and counseling on potential adverse effects (hypocalcemia, infections, dermatologic reactions), baseline serum calcium measurement if not recently available, preparation of the product by nursing staff according to clinic protocol, subcutaneous administration (typically in the upper arm, abdomen, or thigh), and post-injection observation for immediate adverse reaction per facility policy. Billing staff capture the Q5162 HCPCS Level II code along with the appropriate payer information (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare) and any applicable modifiers reflecting service specifics. Typical site of service is an outpatient infusion/injection clinic, physician office, or hospital outpatient department. Typical patient scenario: a 68-year-old woman with osteoporosis and a prior vertebral compression fracture receiving a routine six-month denosumab biosimilar injection during a scheduled clinic visit with prior labs reviewed and documentation of counseling and post-injection observation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|